Editas Medicine (EDIT) Enterprise Value Growth (1y) (2016 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Editas Medicine | 338.62 Mn | 338.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 45.67% |
| Sep 30, 2025 | 37.51% |
| Jun 30, 2025 | 36.05% |
| Mar 31, 2025 | 25.39% |
| Dec 31, 2024 | 16.46% |
| Sep 30, 2024 | 24.18% |
| Jun 30, 2024 | 35.39% |
| Mar 31, 2024 | 6.99% |
| Dec 31, 2023 | 6.15% |
| Sep 30, 2023 | 16.68% |
| Jun 30, 2023 | 4.55% |
| Mar 31, 2023 | 34.79% |
| Dec 31, 2022 | 31.12% |
| Sep 30, 2022 | 24.78% |
| Jun 30, 2022 | 25.88% |
| Mar 31, 2022 | 21.90% |
| Dec 31, 2021 | -24.31% |
| Sep 30, 2021 | -12.63% |
| Jun 30, 2021 | -1.98% |
| Mar 31, 2021 | -50.69% |
| Dec 31, 2020 | 12.04% |
| Sep 30, 2020 | -48.91% |
| Jun 30, 2020 | -88.32% |
| Mar 31, 2020 | -21.32% |
| Dec 31, 2019 | -23.90% |
| Sep 30, 2019 | 1.44% |
| Jun 30, 2019 | 7.60% |
| Mar 31, 2019 | 4.67% |
| Dec 31, 2018 | -12.10% |
| Sep 30, 2018 | -14.14% |
| Jun 30, 2018 | -5.94% |
| Mar 31, 2018 | -2.07% |
| Dec 31, 2017 | -77.60% |
| Sep 30, 2017 | -47.94% |
| Jun 30, 2017 | -49.23% |
| Mar 31, 2017 | -53.38% |
| Dec 31, 2016 | -120.22% |
| Sep 30, 2016 | -28.70% |
| Jun 30, 2016 | -362.69% |
| Mar 31, 2016 | -4,336.78% |